Comparative Efficacy of Intranasal Corticosteroids versus Novel Antihistamines in Allergic Rhinitis
International Journal of Medicine · 30.06.2026 · 8 (6) · 1556-1561
DOI: 10.61336/im/26-06-231 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Medicine, online erschienen am 30.06.2026.
Abstract (Originalsprache)
Background
Allergic rhinitis (AR) is a highly prevalent, IgE-mediated inflammatory disease of the nasal mucosa. While both Intranasal Corticosteroids (INCS) and novel second-generation oral antihistamines (NAHs) are frequently prescribed, continuous debate exists regarding their comparative efficacy in resolving comprehensive symptom profiles, particularly nasal congestion.
Objective
To comparatively evaluate the clinical efficacy, objective airflow improvement, and safety profiles of a highly selective INCS (Fluticasone Furoate) versus a novel non-sedating antihistamine (Bilastine) in patients with moderate-to-severe persistent allergic rhinitis.
Methods
This prospective, randomized, placebo controlled, parallel-group clinical study includes a total of 140 adult patients were randomized into two groups (Group A: Fluticasone Furoate 110 mcg/day; Group B: Bilastine 20 mg/day) for an 8-week duration. The primary efficacy endpoint was the reduction in the Total Nasal Symptom Score (TNSS). Secondary endpoints included Peak Nasal Inspiratory Flow (PNIF) and the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ).
Results
Both pharmacological interventions significantly reduced baseline TNSS (p < 0.001). However, Group A demonstrated a statistically superior reduction in the overall TNSS at week 8 compared to Group B. The disparity was primarily driven by the resolution of nasal congestion, where INCS yielded a 78% improvement versus 34% in the NAH group.
Objective
PNIF measurements corroborated these clinical findings. Both drugs exhibited excellent tolerability profiles with no serious adverse events.
Conclusion
While novel antihistamines provide rapid and effective relief of histamine-driven symptoms (pruritus, sneezing), intranasal corticosteroids exhibit superior overall clinical efficacy in moderate-to-severe AR, primarily due to their profound suppression of late-phase mucosal inflammation and severe nasal congestion.
Zitieren
APA
(2026). Comparative Efficacy of Intranasal Corticosteroids versus Novel Antihistamines in Allergic Rhinitis. International Journal of Medicine, 8(6), 1556-1561. https://doi.org/10.61336/im/26-06-231
Vancouver
Comparative Efficacy of Intranasal Corticosteroids versus Novel Antihistamines in Allergic Rhinitis. International Journal of Medicine. 2026;8(6):1556-1561. doi:10.61336/im/26-06-231
BibTeX
@article{euvimed2026,
title = {Comparative Efficacy of Intranasal Corticosteroids versus Novel Antihistamines in Allergic Rhinitis},
journal = {International Journal of Medicine},
year = {2026},
volume = {8},
number = {6},
pages = {1556--1561},
doi = {10.61336/im/26-06-231}
}
EUVIMED